Clinical Commander

Back to dossier
endo.sheehan-syndrome.core.v1PRODUCTION
endo.sheehan-syndrome.core.v1

Sheehan syndrome (postpartum hypopituitarism)

endocrinologyacutechronicpregnancyadult
Hard-required inputs
0 / 11
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Recognize Sheehan pattern: severe PPH/hypovolemic shock substrate + EITHER acute postpartum refractory shock/hypoglycemia/failure to lactate OR delayed central panhypopituitarism unmasked by stress (Fleseriu JCEM 2016; Karaca Pituitary 2021)

Inputs
3
Actions
0
Advance rule
Set
Advance when

obstetric-hemorrhage substrate present AND acute or delayed hypopituitary pattern recognized (Karaca Pituitary 2021)

Patient inputs (15)

Woman of reproductive age; estrogen/progestin replacement until natural menopause; pregnancy intent affects plan (Fleseriu JCEM 2016)

Severe PPH / hypovolemic shock is the defining etiologic substrate; high index of suspicion driver (Karaca Pituitary 2021; Diri Endocrine 2016)

Failure to lactate is the cardinal early pivot (low/absent prolactin effect) (Karaca Pituitary 2021)

Failure to resume menses / amenorrhea is a classic delayed feature (gonadotropin deficiency) (Karaca Pituitary 2021)

Morning cortisol — low with inappropriately low/normal ACTH = central adrenal insufficiency; draw before steroid but do NOT delay treatment in crisis (Fleseriu JCEM 2016)

Low free T4 with low/normal TSH = central hypothyroidism; TSH is unreliable in central disease (Fleseriu JCEM 2016; Persani JCEM 2018)

Interpreted ONLY alongside free T4 — an inappropriately normal TSH with low free T4 is central hypothyroidism (Persani JCEM 2018)

Hyponatremia from cortisol +/- thyroid deficiency; SIADH-like dilutional pattern; severe Na drives ICU + correction rate ceiling (Fleseriu JCEM 2016)

Hypoglycemia from cortisol +/- GH deficiency, especially peripartum and in delayed crises (Fleseriu JCEM 2016)

Refractory hypotension/shock defines the acute secondary adrenal crisis presentation (Fleseriu JCEM 2016)

Tachycardia with shock; relative bradycardia possible with severe central hypothyroidism (Fleseriu JCEM 2016)

Low IGF-1 supports GH deficiency once other axes are replaced (Fleseriu JCEM 2016)

Early — pituitary enlargement / non-enhancing gland; late — partial or empty sella (Karaca Pituitary 2021)

Inappropriately low/normal ACTH localizes the defect to the pituitary (secondary AI) (Fleseriu JCEM 2016)

Low/absent prolactin correlates with lactation failure and supports the diagnosis (Karaca Pituitary 2021)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (6)

6 need judgement
  • informationallife_threateningpostpartum_adrenal_crisis_refractory_shock — Fleseriu JCEM 2016
    Postpartum (or delayed) hypotension/shock not responding to fluids and vasopressors in a Sheehan substrate — secondary adrenal crisis (Fleseriu JCEM 2016; Diri Endocrine 2016)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningdelayed_presentation_unmasked_by_stress — Karaca Pituitary 2021
    Known/occult Sheehan with chronic under-replacement decompensating during intercurrent illness/surgery/stress (Karaca Pituitary 2021)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveresevere_hyponatremia_lt_125 — Fleseriu JCEM 2016
    Sodium <125 with neuro symptoms in a Sheehan crisis (Fleseriu JCEM 2016)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveresymptomatic_hypoglycemia — Fleseriu JCEM 2016
    Symptomatic hypoglycemia (glucose <70 with neuroglycopenia) from cortisol +/- GH deficiency (Fleseriu JCEM 2016)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverelevothyroxine_before_glucocorticoid — Fleseriu JCEM 2016
    Central hypothyroidism identified with glucocorticoid replacement NOT yet established — levothyroxine initiation is contraindicated until GC on board (Fleseriu JCEM 2016)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatefailure_to_lactate_plus_obstetric_hemorrhage_recognition — Karaca Pituitary 2021
    Failure to lactate after a delivery complicated by severe PPH/hypovolemic shock — the key recognition trigger that should prompt Sheehan workup (Karaca Pituitary 2021)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives severity classification
Loading…

Recommended regimen

Sheehan replacement — acute crisis stabilization FIRST, then ordered axis replacement (GC before T4) (Fleseriu JCEM 2016)
axis: sheehan_replacement_sequencestep 1 - Stage 1 — ACUTE crisis: stress-dose hydrocortisone + fluids + glucose + correct hyponatremia FIRST (Fleseriu JCEM 2016)
Selected step "Stage 1 — ACUTE crisis: stress-dose hydrocortisone + fluids + glucose + correct hyponatremia FIRST (Fleseriu JCEM 2016)" — Postpartum or delayed crisis: refractory shock and/or hypoglycemia and/or severe hyponatremia in a Sheehan substrate (Fleseriu JCEM 2016; Diri Endocrine 2016)
  • hydrocortisone
    first line
    glucocorticoid_short_acting
    100 mg IV/IM bolus STAT, then 50 mg IV q6h OR 200 mg/24h continuous infusion • IV • q6h or continuous infusion
    triggers: sheehan_crisis_suspected, refractory_postpartum_shock, symptomatic_hypoglycemia
    Fleseriu JCEM 2016 — central adrenal insufficiency drives the crisis; empiric stress-dose glucocorticoid is the single most important and mortality-reducing intervention; do NOT delay for cortisol/ACTH
    rxcui 5492
  • dexamethasone
    second line
    glucocorticoid_long_acting
    4 mg IV bolus (only if hydrocortisone unavailable AND a diagnostic cortisol/ACTH window must be preserved) • IV • single dose
    triggers: hydrocortisone_unavailable, preserve_diagnostic_window
    Does not cross-react with the cortisol assay; bridge until hydrocortisone available (Fleseriu JCEM 2016)
    rxcui 3264
  • 0.9% sodium chloride resuscitation + glucose correction
    first line
    crystalloid_and_dextrose
    1 L 0.9% NaCl IV over 1h then 2–3 L over 24h; D50 25 g IV push for glucose <70; correct Na with rate ceiling <8 mEq/L per 24h • IV • continuous + PRN
    triggers: hypovolemia, hypoglycemia, hyponatremia
    Volume + glucose + cautious Na correction concurrent with steroid; high-dose hydrocortisone covers mineralocorticoid effect; Adrogué–Madias ceiling prevents osmotic demyelination (Fleseriu JCEM 2016)
  • obstetric hemorrhage source control
    first line
    procedural_hemostasis
    Uterotonics / tamponade / arterial embolization / surgical hemostasis + transfusion per obstetric protocol when peripartum hemorrhage is ongoing • procedural • as required
    triggers: ongoing_peripartum_hemorrhage
    The ischemic insult is hemorrhage-driven — controlling the bleed and restoring perfusion is part of the acute bundle (Karaca Pituitary 2021)

outpatient playbook — drug actions (5)

  1. 1. hydrocortisone PO chronic
    15-20 mg/day in 2-3 divided doses (larger AM dose) • PO • BID-TID
    trigger: Confirmed central adrenal insufficiency (Fleseriu JCEM 2016)
    Physiologic glucocorticoid replacement FIRST axis (Fleseriu JCEM 2016)
  2. 2. levothyroxine
    1.6 mcg/kg/day PO titrated to free T4 (NOT TSH) • PO • once daily
    trigger: Central hypothyroidism AND GC already established (Fleseriu JCEM 2016)
    Cardinal order preserved in outpatient initiation too (Fleseriu JCEM 2016)
  3. 3. estradiol + cyclical progestin
    Transdermal estradiol 50 mcg/24h + cyclical progestin if uterus • transdermal/PO • continuous + cyclical
    trigger: Premenopausal hypogonadotropic hypogonadism, no contraindication (Fleseriu JCEM 2016)
    Until natural menopause (Fleseriu JCEM 2016)
  4. 4. somatropin
    0.2-0.4 mg SC daily titrated to IGF-1 • SC • once daily
    trigger: Confirmed severe GH deficiency, other axes replaced, no malignancy (Fleseriu JCEM 2016)
    GH replacement where indicated (Fleseriu JCEM 2016)
  5. 5. desmopressin
    Intranasal 10 mcg or PO 0.1 mg titrated • intranasal/PO • titrated
    trigger: Confirmed central DI (rare) (Fleseriu JCEM 2016)
    Only if central DI documented (Fleseriu JCEM 2016)

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Failure to lactate after delivery complicated by severe PPH (Fleseriu JCEM 2016; Karaca Pituitary 2021); Postpartum hypotension/shock not responding to fluids and pressors (Fleseriu JCEM 2016; Diri Endocrine 2016); Delayed: agalactia + failure to resume menses + fatigue/cold intolerance months–years after obstetric hemorrhage (Karaca Pituitary 2021; Kilicli J Endocrinol Invest 2023).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Sheehan syndrome (postpartum hypopituitarism)** (endo.sheehan-syndrome.core.v1).
Phenotype framing: Phenotype: acute postpartum Sheehan crisis vs classic delayed Sheehan panhypopituitarism; distinguish from pituitary apoplexy (acute hemorrhagic into adenoma, headache/visual), lymphocytic hypophysitis (postpartum, autoimmune, often isolated ACTH/central DI, stalk thickening), primary adrenal/thyroid disease, and postpartum thyroiditis (Karaca Pituitary 2021; Diri Endocrine 2016)
Scope: Recognize Sheehan pattern: severe PPH/hypovolemic shock substrate + EITHER acute postpartum refractory shock/hypoglycemia/failure to lactate OR delayed central panhypopituitarism unmasked by stress (Fleseriu JCEM 2016; Karaca Pituitary 2021)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Sheehan replacement — acute crisis stabilization FIRST, then ordered axis replacement (GC before T4) (Fleseriu JCEM 2016)** — step "Stage 1 — ACUTE crisis: stress-dose hydrocortisone + fluids + glucose + correct hyponatremia FIRST (Fleseriu JCEM 2016)".
1. hydrocortisone 100 mg IV/IM bolus STAT, then 50 mg IV q6h OR 200 mg/24h continuous infusion IV q6h or continuous infusion (glucocorticoid_short_acting, first line) — Fleseriu JCEM 2016 — central adrenal insufficiency drives the crisis; empiric stress-dose glucocorticoid is the single most important and mortality-reducing intervention; do NOT delay for cortisol/ACTH
2. dexamethasone 4 mg IV bolus (only if hydrocortisone unavailable AND a diagnostic cortisol/ACTH window must be preserved) IV single dose (glucocorticoid_long_acting, second line) — Does not cross-react with the cortisol assay; bridge until hydrocortisone available (Fleseriu JCEM 2016)
3. 0.9% sodium chloride resuscitation + glucose correction 1 L 0.9% NaCl IV over 1h then 2–3 L over 24h; D50 25 g IV push for glucose <70; correct Na with rate ceiling <8 mEq/L per 24h IV continuous + PRN (crystalloid_and_dextrose, first line) — Volume + glucose + cautious Na correction concurrent with steroid; high-dose hydrocortisone covers mineralocorticoid effect; Adrogué–Madias ceiling prevents osmotic demyelination (Fleseriu JCEM 2016)
4. obstetric hemorrhage source control Uterotonics / tamponade / arterial embolization / surgical hemostasis + transfusion per obstetric protocol when peripartum hemorrhage is ongoing procedural as required (procedural_hemostasis, first line) — The ischemic insult is hemorrhage-driven — controlling the bleed and restoring perfusion is part of the acute bundle (Karaca Pituitary 2021)

Setting playbook (outpatient) — Diagnose delayed Sheehan, establish lifelong individualized replacement in correct sequence, deliver sick-day rules + steroid card + preconception counseling, transition to chronic hypopituitarism management (Fleseriu JCEM 2016; Karaca Pituitary 2021)
5. hydrocortisone PO chronic 15-20 mg/day in 2-3 divided doses (larger AM dose) PO BID-TID — Confirmed central adrenal insufficiency (Fleseriu JCEM 2016) (Physiologic glucocorticoid replacement FIRST axis (Fleseriu JCEM 2016))
6. levothyroxine 1.6 mcg/kg/day PO titrated to free T4 (NOT TSH) PO once daily — Central hypothyroidism AND GC already established (Fleseriu JCEM 2016) (Cardinal order preserved in outpatient initiation too (Fleseriu JCEM 2016))
7. estradiol + cyclical progestin Transdermal estradiol 50 mcg/24h + cyclical progestin if uterus transdermal/PO continuous + cyclical — Premenopausal hypogonadotropic hypogonadism, no contraindication (Fleseriu JCEM 2016) (Until natural menopause (Fleseriu JCEM 2016))
8. somatropin 0.2-0.4 mg SC daily titrated to IGF-1 SC once daily — Confirmed severe GH deficiency, other axes replaced, no malignancy (Fleseriu JCEM 2016) (GH replacement where indicated (Fleseriu JCEM 2016))
9. desmopressin Intranasal 10 mcg or PO 0.1 mg titrated intranasal/PO titrated — Confirmed central DI (rare) (Fleseriu JCEM 2016) (Only if central DI documented (Fleseriu JCEM 2016))

Non-pharmacologic actions:
- Steroid emergency card + MedicAlert ID + prescribed 100 mg IM hydrocortisone kit (Fleseriu JCEM 2016)
- Sick-day rules training — double/triple oral HC for febrile illness; IM 100 mg + ED for vomiting/trauma/surgery (Fleseriu JCEM 2016)
- Preconception counseling for future pregnancies — stress dosing in labor, MFM co-management (Karaca Pituitary 2021)
- Transition-of-care to chronic hypopituitarism management with periodic axis reassessment (Fleseriu JCEM 2016)

AVOID / contraindication checks:
- Never_start_levothyroxine_before_glucocorticoid (Fleseriu JCEM 2016)
- Do_not_delay_empiric_hydrocortisone_for_diagnostic_cortisol_in_crisis (Fleseriu JCEM 2016)
- Under_replacement_of_glucocorticoid_during_stress_or_intercurrent_illness_precipitates_crisis (Fleseriu JCEM 2016; Karaca Pituitary 2021)
- Correct_Na_max_8_mEq_per_24h_to_prevent_osmotic_demyelination (Fleseriu JCEM 2016)
- Fludrocortisone_not_routinely_indicated_in_secondary_AI (Karaca Pituitary 2021)
- Titrate_levothyroxine_by_free_T4_not_TSH_in_central_hypothyroidism (Persani JCEM 2018)

Monitoring

Regimen monitoring:
- BP + HR q15min until stable in acute crisis (Fleseriu JCEM 2016)
- Na + glucose q4-6h x first 24h with <8 mEq per 24h correction ceiling (Fleseriu JCEM 2016)
- mental status q2h in acute crisis (Fleseriu JCEM 2016)
- free T4 (NOT TSH) for levothyroxine titration in central hypothyroidism (Persani JCEM 2018)
- clinical glucocorticoid adequacy + weight + BP on chronic hydrocortisone (Fleseriu JCEM 2016)
- IGF-1 within age/sex range for GH titration (Fleseriu JCEM 2016)
- urine output + serum Na on desmopressin to avoid dilutional hyponatremia (Fleseriu JCEM 2016)

Setting (outpatient) monitoring:
- Clinical glucocorticoid adequacy + weight + BP (Fleseriu JCEM 2016)
- Free T4 (NOT TSH) for levothyroxine titration (Persani JCEM 2018)
- IGF-1 within age/sex range for GH (Fleseriu JCEM 2016)
- Serum Na on desmopressin; periodic bone density (Fleseriu JCEM 2016)

Follow-up plan: Lifelong individualized replacement, sick-day rules + emergency hydrocortisone IM kit + steroid card + medical alert ID, preconception counseling for future pregnancies, transition to chronic hypopituitarism management, family/obstetric documentation (Fleseriu JCEM 2016; Karaca Pituitary 2021)
- Close-out criterion: sick-day rules taught; steroid card + emergency kit issued; preconception counseling delivered; chronic endocrine follow-up scheduled (Fleseriu JCEM 2016)

Monitoring phase: Acute: hourly vitals, q4–6h Na + glucose, mental status, Na correction <8 mEq/L/24h ceiling; chronic: clinical replacement adequacy, free T4 (NOT TSH) for levothyroxine titration, IGF-1 for GH, BP/weight/electrolytes on hydrocortisone/fludrocortisone (Fleseriu JCEM 2016; Persani JCEM 2018)

Disposition

Current setting: outpatient — Diagnose delayed Sheehan, establish lifelong individualized replacement in correct sequence, deliver sick-day rules + steroid card + preconception counseling, transition to chronic hypopituitarism management (Fleseriu JCEM 2016; Karaca Pituitary 2021)

Disposition criteria:
- Stable on chronic individualized replacement, sick-day competent, steroid card + kit issued, preconception counseling done, endocrine follow-up scheduled (Fleseriu JCEM 2016; Karaca Pituitary 2021)

Escalation triggers (move to higher acuity):
- Intercurrent illness with inadequate stress dosing → ED + IV hydrocortisone (Fleseriu JCEM 2016; Karaca Pituitary 2021)
- New shock/hyponatremia/hypoglycemia → treat as adrenal crisis, route to ED (Fleseriu JCEM 2016)

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Postpartum (or delayed) hypotension/shock not responding to fluids and vasopressors in a Sheehan substrate — secondary adrenal crisis (Fleseriu JCEM 2016; Diri Endocrine 2016)
- [LIFE_THREATENING] Known/occult Sheehan with chronic under-replacement decompensating during intercurrent illness/surgery/stress (Karaca Pituitary 2021)
- [SEVERE] Sodium <125 with neuro symptoms in a Sheehan crisis (Fleseriu JCEM 2016)

Citations

- 2016 Endocrine Society Hormonal Replacement in Hypopituitarism in Adults (Fleseriu JCEM 2016); Sheehan syndrome reviews (Diri/Karaca Endocrine 2015; Kilicli Gynecol Endocrinol 2012); 2018 ETA Guidelines on Central Hypothyroidism (Persani Eur Thyroid J 2018) [PMID:27736313](https://pubmed.ncbi.nlm.nih.gov/27736313/)
- Cited evidence (PMID 26323346) [PMID:26323346](https://pubmed.ncbi.nlm.nih.gov/26323346/)
- Cited evidence (PMID 23245206) [PMID:23245206](https://pubmed.ncbi.nlm.nih.gov/23245206/)
- Cited evidence (PMID 30374425) [PMID:30374425](https://pubmed.ncbi.nlm.nih.gov/30374425/)

Last reconciled with current guidelines: 2026-05-22.
References
  • 2016 Endocrine Society Hormonal Replacement in Hypopituitarism in Adults (Fleseriu JCEM 2016); Sheehan syndrome reviews (Diri/Karaca Endocrine 2015; Kilicli Gynecol Endocrinol 2012); 2018 ETA Guidelines on Central Hypothyroidism (Persani Eur Thyroid J 2018) — PMID:27736313
  • Cited evidence (PMID 26323346) — PMID:26323346
  • Cited evidence (PMID 23245206) — PMID:23245206
  • Cited evidence (PMID 30374425) — PMID:30374425